Maria Teresa Valenti

Summary

Affiliation: University of Verona
Country: Italy

Publications

  1. ncbi Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells
    Maria Teresa Valenti
    Department of Biomedical and Surgical Sciences, Medicina Interna D, University of Verona, Piazzale Scuro 37134 Verona, Italy
    Bone 43:1084-92. 2008
  2. ncbi The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation
    Maria Teresa Valenti
    Department of Medicine, University of Verona Piazzale L, Scuro, Verona, Italy
    Arthritis Res Ther 12:R163. 2010
  3. ncbi Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis
    Luca Dalle Carbonare
    University of Verona, Verona, Italy
    Arthritis Rheum 60:3356-65. 2009
  4. ncbi The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells
    Maria Teresa Valenti
    Department of Biomedical and Surgical Sciences, Clinic of Internal Medicine D University of Verona, Italy
    Eur J Pharmacol 580:36-42. 2008
  5. ncbi Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion
    Francesco Bertoldo
    Department of Biochemical and Surgical Sciences, University of Verona, Verona, Italy
    J Bone Miner Res 25:447-54. 2010
  6. ncbi The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?
    Maria Teresa Valenti
    Department of Biomedical and Surgical Sciences, University of Verona, Italy
    BMC Cancer 6:49. 2006
  7. ncbi Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPAR?2 expression in MSCs-like of osteoporotic patients
    Maria Teresa Valenti
    Department of Medicine, Clinica di Medicina Interna, Sezione D, University of Verona, Verona, Italy
    PLoS ONE 6:e20363. 2011
  8. ncbi Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion
    Elisa Tinazzi
    Department of Medicine, University of Verona, le LA Scuro, Verona, Italy
    Arthritis Res Ther 12:R131. 2010
  9. ncbi Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
    Luca Dalle Carbonare
    Clinic of Internal Medicine D, Department of Medicine, University of Verona, Italy
    Drug Healthc Patient Saf 2:121-37. 2010
  10. ncbi A novel splicing mutation in FKBP10 causing osteogenesis imperfecta with a possible mineralization defect
    Giacomo Venturi
    Department of Life and Reproduction Sciences, Pediatric Clinic, University of Verona, Italy
    Bone 50:343-9. 2012

Collaborators

Detail Information

Publications10

  1. ncbi Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells
    Maria Teresa Valenti
    Department of Biomedical and Surgical Sciences, Medicina Interna D, University of Verona, Piazzale Scuro 37134 Verona, Italy
    Bone 43:1084-92. 2008
    ....
  2. ncbi The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation
    Maria Teresa Valenti
    Department of Medicine, University of Verona Piazzale L, Scuro, Verona, Italy
    Arthritis Res Ther 12:R163. 2010
    ..The purpose of this study was to evaluate the effects of risedronate (Ris) in the modulation of bone formation in rats with glucocorticoid (GC)-induced osteoporosis by histomorphometric, immunohistochemical and gene expression analyses...
  3. ncbi Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis
    Luca Dalle Carbonare
    University of Verona, Verona, Italy
    Arthritis Rheum 60:3356-65. 2009
    ..The present study was undertaken to evaluate a possible alteration of osteogenic gene expression as a mechanism contributing to bone loss...
  4. ncbi The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells
    Maria Teresa Valenti
    Department of Biomedical and Surgical Sciences, Clinic of Internal Medicine D University of Verona, Italy
    Eur J Pharmacol 580:36-42. 2008
    ..These results support the hypothesis that prostatic cancer cells are targeted by amino-bisphosphonates also through a different mechanism from the mevalonate pathway...
  5. ncbi Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion
    Francesco Bertoldo
    Department of Biochemical and Surgical Sciences, University of Verona, Verona, Italy
    J Bone Miner Res 25:447-54. 2010
    ..However, if confirmed, it should have some practical implications in preventing APR...
  6. ncbi The effect of bisphosphonates on gene expression: GAPDH as a housekeeping or a new target gene?
    Maria Teresa Valenti
    Department of Biomedical and Surgical Sciences, University of Verona, Italy
    BMC Cancer 6:49. 2006
    ..They exert their effects mainly by inhibiting the mevalonate pathway but also by modulating the expression of many genes not only in osteoclasts but also in cancer cells...
  7. ncbi Role of ox-PAPCs in the differentiation of mesenchymal stem cells (MSCs) and Runx2 and PPAR?2 expression in MSCs-like of osteoporotic patients
    Maria Teresa Valenti
    Department of Medicine, Clinica di Medicina Interna, Sezione D, University of Verona, Verona, Italy
    PLoS ONE 6:e20363. 2011
    ..Modified lipoproteins derived from the oxidation of arachidonate-containing phospholipids (ox-PAPCs: POVPC, PGPC and PEIPC) are considered important factors in atherogenesis...
  8. ncbi Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion
    Elisa Tinazzi
    Department of Medicine, University of Verona, le LA Scuro, Verona, Italy
    Arthritis Res Ther 12:R131. 2010
    ..We aimed at studying the gene expression profile of circulating endothelial cells and the effects of iloprost infusion and gene expression in patients with systemic sclerosis...
  9. ncbi Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
    Luca Dalle Carbonare
    Clinic of Internal Medicine D, Department of Medicine, University of Verona, Italy
    Drug Healthc Patient Saf 2:121-37. 2010
    ..The most recent weekly and monthly formulations, and in particular the yearly infusion of zoledronate, significantly improve persistence with treatment, and optimize clinical, densitometric, and antifracture outcomes...
  10. ncbi A novel splicing mutation in FKBP10 causing osteogenesis imperfecta with a possible mineralization defect
    Giacomo Venturi
    Department of Life and Reproduction Sciences, Pediatric Clinic, University of Verona, Italy
    Bone 50:343-9. 2012
    ....